Loading clinical trials...
Loading clinical trials...
An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD)
Conditions
Interventions
pegaptanib sodium
Locations
20
United States
Doheny Eye Institute
Los Angeles, California, United States
Connecticut Retina Consultants, L.L.C.
Bridgeport, Connecticut, United States
New England Retina Associates
Hamden, Connecticut, United States
Retina Health Center
Fort Myers, Florida, United States
Retina Associates
New Orleans, Louisiana, United States
Cumberland Valley Retina Center
Hagerstown, Maryland, United States
Start Date
July 1, 2004
Last Updated
August 30, 2005
NCT05913063
NCT07446582
NCT06779773
NCT06990269
NCT06970665
NCT07160179
Lead Sponsor
Eyetech Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions